OTC and ornithine carbamoyltransferase deficiency: However, the death of one patient, 17-year-old J.G., after transfection with an adenoviral vector (different from the one used nowadays) encoding the OTC gene to treat the ornithine transcarbamylase deficiency (OTCD) [143] he suffered from was enough to stop any enthusiasm around the idea of gene therapy.